CHEK2 and skin basal cell carcinoma: Current evidence suggests an elevated risk of BCC, the most common NMSC, in patients with LFS [43, 44], and limited evidence supports the connection of CHEK2 [109] and BRCA2 [87] with elevated BCC risk.